Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04081194
Collaborator
(none)
15
1
38
0.4

Study Details

Study Description

Brief Summary

Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Cell free circulating free nucleic acids is new substrates for laboratory diagnostics in a number of medical areas including oncology, transfusion medicine, gynecology/obstetrics, inflammatory and autoimmune diseases etc.There are various qualities of cell free nucleic acids. In oncology, it has been shown that the early detection of cell free nucleic acids originating from the tumour preceeds the diagnostic detection of clinical relapse as done by imaging techniques or clinical symptoms by 6-8- months.

    Exosomes are small, lipid bilayer membrane vesicles (30-100 nm) that are released from all cell types into the extracellular space. These tiny membrane vesicles transmit EV-mediated signals by proteins, lipids, nucleic acids and sugars, and the unique molecular pattern of this package direct the type of extracellular signal to be transmitted to target cells. Interest in exosomes range from their mode of action and various functions in the body to more practical applications such as development of biomarkers based on analysis of their RNA and protein content and their use in clinical diagnostics. It was proposed that micro RNAs are transferred through exosomes to recipient cells and can there mediate repression of their mRNA targets.

    The use of highly expensive targeted therapies (e.g. tyrosine kinase inhibitors or PARP inhibitors) may become obsolete during therapy due to changes in the mutational molecular profile of the malignant tumour. Indeed, if early detection of cell free nucleic acids suggest therapy failure, new stratification of the patient and changed therapy modalities may be possible in the future, thus helping to prolong overall survival of tumour patients.

    Aims of the Research:
    • To isolate exosomes as a stable source of cell free nucleic acids.

    • To perform protein profiling on the isolated exosomes.

    • To isolate nucleic acids from exosomes for analysis.

    • To define and develop standards and protocols for cell free nucleic acids analysis particularly regarding epigenetic alterations with emphasis on DNA methylation.

    • Optimizing of pre-analytical process to improve the pre-analytical aspects of assays.

    • To test the stability of methylated compared to non-methylated circulating DNA under various pre-analytical conditions.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    15 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.
    Actual Study Start Date :
    Oct 1, 2016
    Anticipated Primary Completion Date :
    Nov 1, 2019
    Anticipated Study Completion Date :
    Dec 1, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    case group, Melanoma Patients

    15 patients of with Melanoma, Age between 40 and 90 years. -Withdrawal of Blood sample, Isolation of Exosomes: Bradford protein assay And Qubit protein assay. Bioanalyzer. Real time PCR.

    control group

    10 Persons without Melanoma, age > 40 years -Withdrawal of Blood sample, Isolation of Exosomes: Bradford protein assay And Qubit protein assay. Bioanalyzer. Real time PCR.

    Outcome Measures

    Primary Outcome Measures

    1. Isolation of Exosomes as a stable source of nucleic acid as an early Detection Method to diagnose Melanoma. [one year]

      Real time PCR for detecting the presence of Melanoma relevant nucleic acids isolated of Exososmes.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • patients with Melanoma
    Exclusion Criteria:
    • patients with other types of malignancies

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Assiut University Hospitals- Faculty of Medicine Assiut Egypt 71111

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Study Director: Hesham A Abdel-Baset, Prof., Assiut University- Faculty of Medicine- Clinical Pathology dept.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sara Alameldin, Assisstent Lecturer, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04081194
    Other Study ID Numbers:
    • Sara Alameldin 20.06.2016
    First Posted:
    Sep 9, 2019
    Last Update Posted:
    Sep 17, 2019
    Last Verified:
    Sep 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Sep 17, 2019